CXCL1 and neoplasm: This result not only enriches the existing understanding of the pro‐tumour mechanism of CXCL1 from the novel perspective of EVs but also provides experimental evidence for the approved combination regimen of nab‐paclitaxel and a PD‐L1 monoclonal antibody (e.g., atezolizumab) in patients with advanced TNBC (Schmid et al., 2018; Schmid et al., 2020).